Robert C. Bast Jr.

Robert C. Bast Jr.'s AcademicInfluence.com Rankings

Robert C. Bast Jr.

Philosophy

#3392

World Rank

#5496

Historical Rank

#1083

USA Rank

Logic

#1130

World Rank

#1795

Historical Rank

#364

USA Rank

philosophy Degrees

Download Badge

Philosophy

Robert C. Bast Jr.'s Degrees

Masters Medicine University of Texas Medical Branch
Bachelors Chemistry Rice University

Why Is Robert C. Bast Jr. Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Robert Clinton Bast Jr., is an American physician-scientist who is currently Vice President for Translational Research at the University of Texas M.D. Anderson Cancer Center. Bast is best known for the discovery of CA125, a serum biomarker for ovarian cancer that has contributed to the care of ovarian cancer patients worldwide. His research spans early detection, enhancing chemotherapy and understanding regulation of dormancy and the role of autophagy in breast and ovarian cancer.

(See a Problem?)

Robert C. Bast Jr.'s Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Guidelines for the use and interpretation of assays for monitoring autophagy (2012) (6925)
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (2012) (2913)
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. (1983) (2040)
Reactivity of a monoclonal antibody with human ovarian carcinoma. (1981) (1616)
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. (2006) (1441)
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. (2007) (1333)
The biology of ovarian cancer: new opportunities for translation (2009) (1317)
Rethinking ovarian cancer: recommendations for improving outcomes (2011) (1148)
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. (2007) (991)
The CA 125 tumour-associated antigen: a review of the literature. (1989) (972)
Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer (2004) (936)
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. (2001) (886)
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 (2021) (811)
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer (2015) (778)
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. (1996) (760)
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. (1988) (738)
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. (2009) (734)
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. (2008) (666)
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. (2016) (656)
Tissue Distribution of a Coelomic- Epithelium‐Related Antigen Recognized by the Monoclonal Antibody OC125 (1983) (620)
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. (2008) (603)
Ovarian cancer: screening, treatment, and followup. (1995) (579)
Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor (1994) (522)
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. (1993) (514)
New tumor markers: CA125 and beyond (2005) (503)
Overexpression and mutation of p53 in epithelial ovarian cancer. (1991) (491)
Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis (2004) (445)
The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. (2008) (414)
Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. (1991) (393)
High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. (1988) (382)
Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. (1983) (366)
Potential markers that complement expression of CA125 in epithelial ovarian cancer. (2005) (362)
Holland-Frei Cancer Medicine (2016) (361)
Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer (2010) (360)
Prospective Evaluation of Serum CA 125 Levels for Early Detection of Ovarian Cancer (1992) (322)
Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. (1984) (322)
The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis (2006) (321)
Elevated serum concentrations of CA-125 in patients with advanced endometriosis. (1986) (315)
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. (2017) (311)
NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. (1999) (311)
Patterns of Gene Expression in Different Histotypes of Epithelial Ovarian Cancer Correlate with Those in Normal Fallopian Tube, Endometrium, and Colon (2005) (299)
CA125 Antigen Levels in Obstetric and Gynecologic Patients (1984) (290)
Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. (2010) (289)
A Genetically Defined Model for Human Ovarian Cancer (2004) (288)
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers (2008) (284)
Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens (2011) (283)
Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. (1984) (279)
Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. (2012) (278)
Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway (1999) (276)
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. (2015) (271)
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients (2012) (266)
Development of a multimarker assay for early detection of ovarian cancer. (2010) (262)
BCG and cancer (first of two parts). (2010) (259)
Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. (2005) (256)
Communication skills training in oncology (1999) (248)
Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. (1991) (238)
AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN CALLA-POSITIVE ACUTE LYMPHOBLASTIC LEUKAEMIA AFTER IN-VITRO TREATMENT WITH J5 MONOCLONAL ANTIBODY AND COMPLEMENT (1982) (238)
Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers (1995) (234)
Overexpression and mutation of p53 in endometrial carcinoma. (1992) (231)
Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. (1986) (228)
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx. (2019) (227)
Status of tumor markers in ovarian cancer screening. (2003) (220)
BCG and cancer. (1974) (212)
Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. (2008) (212)
Elevation of multiple serum markers in patients with stage I ovarian cancer. (1993) (207)
Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. (1988) (204)
Mechanisms for Lysophosphatidic Acid-induced Cytokine Production in Ovarian Cancer Cells* (2004) (197)
Tumor Necrosis Factor α as an Autocrine and Paracrine Growth Factor for Ovarian Cancer: Monokine Induction of Tumor Cell Proliferation and Tumor Necrosis Factor α Expression (1993) (190)
Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer (2015) (187)
Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. (1993) (184)
Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. (1994) (184)
Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. (1993) (182)
Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. (2003) (179)
Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition (1997) (176)
Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. (1985) (174)
HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy (2006) (170)
A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer (2011) (169)
Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen. (1984) (168)
Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. (2012) (167)
The Role of Cyclin-dependent Kinase Inhibitor p27Kip1 in Anti-HER2 Antibody-induced G1 Cell Cycle Arrest and Tumor Growth Inhibition* (2003) (167)
Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down‐regulated in human ovarian cancers by loss of heterozygosity and promoter methylation (2008) (164)
Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. (1992) (163)
Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. (2004) (161)
Phase 1b‐2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancer (2011) (160)
Multivariable analysis of DNA ploidy, p53, and HER‐2/neu as prognostic factors in endometrial cancer (1994) (160)
Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. (1991) (160)
Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. (1999) (159)
Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. (1994) (158)
High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. (1980) (157)
Correlation between CpG methylation profiles and hormone receptor status in breast cancers (2007) (155)
Use of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer (2004) (154)
HER2-targeting Antibodies Modulate the Cyclin-dependent Kinase Inhibitor p27Kip1 via Multiple Signaling Pathways (2005) (153)
Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. (1985) (150)
Improving physician-patient communication in cancer care: outcome of a workshop for oncologists. (1997) (150)
Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. (1996) (148)
Preoperative Evaluation of Serum CA 125 Levels in Patients With Primary Epithelial Ovarian Cancer (1986) (147)
Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. (1989) (146)
1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology. (1998) (145)
Cell Origins of High-Grade Serous Ovarian Cancer (2018) (140)
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
Early detection of ovarian cancer: promise and reality. (2002) (139)
ANTI-B1 MONOCLONAL ANTIBODY AND COMPLEMENT TREATMENT IN AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR RELAPSED B-CELL NON-HODGKIN'S LYMPHOMA (1984) (139)
The p53 tumor suppressor gene frequently is altered in gynecologic cancers. (1994) (138)
Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy (2011) (137)
The effect of LPS on expression of the early "competence" genes JE and KC in murine peritoneal macrophages. (1987) (136)
The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis (2006) (136)
Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta. (1992) (135)
Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy (2005) (134)
Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. (1996) (133)
Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. (2016) (133)
SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. (2010) (128)
High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial. (1986) (125)
Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement. (1983) (125)
Prevention and early detection of ovarian cancer: mission impossible? (2007) (124)
Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. (2016) (122)
CA 125 serum levels correlated with second-look operations among ovarian cancer patients. (1986) (121)
Inhibition of Breast and Ovarian Tumor Growth through Multiple Signaling Pathways by Using Retrovirus-mediated Small Interfering RNA against Her-2/neu Gene Expression* (2004) (120)
Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta. (2001) (119)
Secretion of extracellular matrix‐degrading proteinases is increased in epithelial ovarian carcinoma (1994) (118)
CRITICAL REVIEW OF PREVIOUSLY REPORTED ANIMAL STUDIES OF TUMOR IMMUNOTHERAPY WITH NON‐SPECIFIC IMMUNOSTIMULANTS (1976) (117)
A 2‐stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early‐stage incident cancers and demonstrates high positive predictive value (2013) (117)
p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. (1992) (115)
Stanniocalcin 1 and ovarian tumorigenesis. (2010) (115)
An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. (1988) (111)
Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3. (2011) (111)
CA 125 in ovarian cancer: advances and controversy. (1998) (108)
Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection (1995) (107)
Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. (1994) (107)
Linking genomic reorganization to tumor initiation via the giant cell cycle (2016) (107)
OVX1, macrophage‐colony stimulating factor, and CA‐125‐II as tumor markers for epithelial ovarian carcinoma (2001) (106)
A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1. (1994) (106)
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. (2007) (105)
4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. (1991) (105)
Current state of biomarker development for clinical application in epithelial ovarian cancer. (2010) (103)
Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. (2010) (102)
Treatment of murine peritoneal macrophages with bacterial lipopolysaccharide alters expression of c-fos and c-myc oncogenes. (1986) (101)
Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. (1984) (100)
ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers (2003) (98)
Activating and Propagating Polyclonal Gamma Delta T Cells with Broad Specificity for Malignancies (2014) (98)
The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade (2010) (97)
Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. (1999) (96)
Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha. (1992) (96)
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. (2003) (95)
The role of biomarkers in the management of epithelial ovarian cancer (2017) (95)
Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. (1985) (94)
Molecular approaches to personalizing management of ovarian cancer. (2011) (94)
Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. (2003) (94)
Somatic activation of rasK gene in a human ovarian carcinoma. (1984) (93)
Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer: II. Relationship between receptor expression and response to epidermal growth factor (1991) (91)
Cell growth regulation in epithelial ovarian cancer (1993) (90)
Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway (2016) (90)
Clinically Relevant microRNAs in Ovarian Cancer (2014) (89)
Cutaneous basophil hypersensitivity. 3. Participation of the basophil in hypersensitivity to antigen-antibody complexes, delayed hypersensitivity and contact allergy. Passive transfer. (1971) (87)
Overexpression of MEKK3 Confers Resistance to Apoptosis through Activation of NFκB* (2004) (87)
Genes Affecting the Cell Cycle, Growth, Maintenance, and Drug Sensitivity Are Preferentially Regulated by Anti-HER2 Antibody through Phosphatidylinositol 3-Kinase-AKT Signaling* (2004) (86)
Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms (1983) (86)
The Role of Peptide Growth Factors in Epithelial Ovarian Cancer (1990) (86)
Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. (1996) (86)
Expression of p16 induces transcriptional downregulation of the RB gene (1998) (86)
Prevention of ovarian cancer: intraepithelial neoplasia. (2003) (84)
Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. (1991) (84)
Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial (2012) (84)
Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. (2012) (83)
Autologous bone marrow transplantation for acute lymphoblastic leukemia. (1989) (83)
Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement. (1985) (83)
Dasatinib induces autophagic cell death in human ovarian cancer (2010) (83)
Transforming growth factor‐beta inhibits proliferation of human ovarian cancer cells obtained from ascites (1994) (82)
Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. (2002) (82)
Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. (1993) (82)
Translational Crossroads for Biomarkers (2005) (81)
Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. (2005) (81)
Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta. (1995) (81)
Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression (2017) (81)
Lysophosphatidic Acid Is a Major Regulator of Growth-Regulated Oncogene α in Ovarian Cancer (2006) (79)
Lysophosphatidylcholine Stimulates Activator Protein 1 and the c-Jun N-terminal Kinase Activity* (1997) (79)
Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2. (1991) (78)
Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas. (1994) (78)
Preoperative Serum Tumor-Associated Antigen Levels in Women With Pelvic Masses (1990) (78)
Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells. (1993) (78)
Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. (1999) (78)
Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. (2007) (78)
The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways (2012) (77)
Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. (1987) (76)
Antibody‐induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c‐erbb‐2 (her‐2/neu) gene product p185 (1993) (76)
Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. (1983) (75)
Epigenetic Regulation of ARHI in Breast and Ovarian Cancer Cells (2003) (74)
Growth regulation and transformation of ovarian epithelium (2010) (74)
The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas. (2013) (73)
Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. (2003) (73)
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. (2012) (73)
Differential Diagnosis of a Pelvic Mass: Improved Algorithms and Novel Biomarkers (2012) (72)
Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms. (2003) (72)
Overexpression of kallikrein 10 in epithelial ovarian carcinomas. (2003) (72)
Personalizing therapy for ovarian cancer: BRCAness and beyond. (2010) (72)
Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. (1994) (72)
Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers (2010) (71)
Epidermal growth factor receptor expression in normal and malignant endometrium. (1989) (71)
Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel (2011) (70)
CA 125 and the detection of recurrent ovarian cancer (2010) (69)
Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. (2011) (68)
Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. (2003) (68)
Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. (1994) (67)
Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. (2007) (66)
Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. (2007) (66)
Co‐expression of human cancer‐associated epitopes on mucin molecules (1987) (65)
Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes. (1983) (65)
Expression of α6 and β4 integrins in serous ovarian carcinoma correlates with expression of the basement membrane protein laminin (1996) (65)
ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7 (2014) (64)
Progress in the management of gynecologic cancer: consensus summary statement. (2003) (63)
Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers. (2006) (62)
Interindividual and intraindividual variations in aryl hydrocarbon hydroxylase in monocytes from monozygotic and dizygotic twins. (1977) (62)
The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. (1999) (62)
Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer (2012) (62)
Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome (2012) (62)
Expression of the Tumor Suppressor Gene ARHI in Epithelial Ovarian Cancer Is Associated with Increased Expression of p21WAF1/CIP1 and Prolonged Progression-Free Survival (2004) (62)
Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. (1994) (61)
Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis1 (2003) (61)
Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. (2006) (60)
Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. (1991) (58)
Screening for ovarian cancer: imaging challenges and opportunities for improvement (2018) (58)
Acquired cellular immunity: extracellular killing of Listeria monocytogenes by a product of immunologically activated macrophages. (1974) (58)
Fluorescence spectroscopy for in vivo characterization of ovarian tissue (2001) (57)
Biomarkers, Surrogate End Points, and the Acceleration of Drug Development for Cancer Prevention and Treatment (2004) (57)
Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. (2000) (57)
Targeted therapy for epithelial ovarian cancer: Current status and future prospects (2003) (57)
Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 Workshop. (1996) (57)
ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers (2000) (56)
Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. (2001) (56)
Low-grade serous carcinoma: new concepts and emerging therapies. (2013) (56)
The duke afm program intensive induction chemotherapy for metastatic breast cancer (1990) (55)
Aryl hydrocarbon (benzo(a)pyrene) hydroxylase in human peripheral blood monocytes (1974) (54)
A Multiplexable, Microfluidic Platform for the Rapid Quantitation of a Biomarker Panel for Early Ovarian Cancer Detection at the Point-of-Care (2014) (54)
Development of an assay for aryl hydrocarbon (benzo(a)pyrene) hydroxylase in human peripheral blood monocytes. (1976) (53)
MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse. (2008) (53)
Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma. (1990) (53)
Modulating microtubule stability enhances the cytotoxic response of cancer cells to Paclitaxel. (2011) (53)
Epithelial Ovarian Cancer (2003) (52)
The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. (1990) (52)
Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15‐3 and TAG 72.3 (1993) (52)
Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias. (1993) (51)
Individualized care for patients with cancer - a work in progress. (2004) (51)
More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis. (2011) (51)
Transcriptional and Posttranscriptional Down-Regulation of the Imprinted Tumor Suppressor Gene ARHI (DRAS3) in Ovarian Cancer (2006) (51)
High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. (1990) (50)
ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts (2015) (50)
Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma. (1985) (50)
Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. (2003) (49)
Elimination of malignant clonogenic breast cancer cells from human bone marrow. (1989) (48)
Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: Discrimination of benign from malignant disease (1989) (48)
Urinary levels of Bcl-2 are elevated in ovarian cancer patients. (2008) (48)
Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors. (1981) (47)
Principles of Medical Oncology (2003) (47)
CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovary. (1989) (47)
Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. (2003) (47)
How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above. (2007) (47)
Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C α activity (2001) (47)
Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma. (1985) (46)
Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare. (2004) (45)
Early Detection of Ovarian Cancer. (2018) (45)
The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. (1997) (45)
Differential induction by interferons of major histocompatibility complex-encoded and non-major histocompatibility complex-encoded antigens in human breast and ovarian carcinoma cell lines. (1989) (44)
ALTERED IMMUNOLOGIC RECONSTITUTION AFTER STANDARD‐DOSE CHEMOTHERAPY OR HIGH‐DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE MARROW SUPPORT (1988) (44)
A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis. (2012) (44)
Pathogenesis of Ovarian Cancers (1994) (44)
Elimination of leukemic cells from rat bone marrow using antibody and complement. (1981) (43)
Genomic structure and promoter characterization of an imprinted tumor suppressor gene ARHI. (2001) (43)
A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel (2016) (43)
Lymphocyte Cytotoxicity in the Peritoneal Cavity and Blood of Patients With Ovarian Cancer (1984) (43)
Programmable Bio-Nano-Chip Systems for Serum CA125 Quantification: Toward Ovarian Cancer Diagnostics at the Point-of-Care (2012) (42)
Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells (2007) (42)
Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer (2017) (41)
A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells. (2005) (41)
Malignant transformation of ovarian epithelium. (1992) (41)
Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells. (2012) (41)
Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. I. Activation of peritoneal cells to mediate antibody-dependent cytotoxicity. (1979) (40)
FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization. (2011) (40)
CA125/MUC16 Is Dispensable for Mouse Development and Reproduction (2009) (40)
Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential. (1989) (40)
Expression of BAG-1 and BcL-2 Proteins Before and After Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer (2004) (39)
Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation (2018) (39)
Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest (2011) (39)
RAS-related GTPases DIRAS1 and DIRAS2 induce autophagic cancer cell death and are required for autophagy in murine ovarian cancer cells (2018) (39)
Downregulation of TRIM27 expression inhibits the proliferation of ovarian cancer cells in vitro and in vivo (2016) (39)
Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. (1998) (38)
Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy‐mediated drug resistance in ovarian cancer cells, xenografts, and patient‐derived xenograft models (2019) (38)
Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. (1994) (38)
Pros and cons of gynecologic tumor markers (1987) (38)
The human ARHI tumor suppressor gene inhibits lactation and growth in transgenic mice. (2000) (38)
Novel Approaches to Ovarian Cancer Screening (2019) (38)
Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates. (1986) (38)
CA-125 Level as a Prognostic Indicator in Type I and Type II Epithelial Ovarian Cancer (2013) (37)
Fluorescence spectroscopy as a biomarker in a cell culture and in a nonhuman primate model for ovarian cancer chemopreventive agents. (2002) (37)
Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB (2016) (37)
Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. (1994) (37)
CA 125 and polymorphic epithelial mucin as serum tumor markers (1988) (37)
Combined use of biomarkers for detection of ovarian cancer in high-risk women (2010) (37)
Early detection of ovarian cancer. (2008) (36)
Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer (2016) (36)
Biomarkers and Strategies for Early Detection of Ovarian Cancer (2020) (36)
Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathway (2013) (36)
Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies (2016) (35)
Regression of established tumors and induction of tumor immunity by intratumor chemotherapy. (1976) (35)
A novel hTERT promoter–driven E1A therapeutic for ovarian cancer (2009) (35)
Clinical trials with human tumor necrosis factor: in vivo and in vitro effects on human mononuclear phagocyte function. (1988) (34)
Expression of cell regulatory proteins in ovarian borderline tumors (1996) (34)
MEKK3 expression correlates with nuclear factor κ B activity and with expression of antiapoptotic genes in serous ovarian carcinoma (2009) (34)
Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9. (2013) (33)
The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. (2011) (33)
Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer (2016) (33)
The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. (1993) (33)
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356 (2016) (33)
Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model (2005) (33)
Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution. (1999) (33)
Weight Loss Upregulates the Small GTPase DIRAS3 in Human White Adipose Progenitor Cells, Which Negatively Regulates Adipogenesis and Activates Autophagy via Akt–mTOR Inhibition (2016) (32)
INDUCTION OF TUMOR IMMUNITY BY INTRATUMORAL CHEMOTHERAPY (1976) (32)
Bystander suppression of tumor growth: evidence that specific targets and bystanders are damaged by injury to a common microvasculature. (1982) (32)
HETEROGENEITY OF THE CELLULAR IMMUNE RESPONSE (1971) (31)
Editorial :Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). DOI: 10.1080/15548627.2015.1100356;WOS:000373595400001; 2-s2.0-85013763791&;PMID: 26799652 (2016) (31)
Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin‐1, interleukin‐6 and tumor necrosis factor‐α (1992) (31)
Detection of breast carcinoma cells in human bone marrow using fluorescence-activated cell sorting and conventional cytology. (1990) (31)
Coevolution of neoplastic epithelial cells and multilineage stroma via polyploid giant cells during immortalization and transformation of mullerian epithelial cells (2016) (31)
Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer (2017) (31)
FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3. (2013) (31)
Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells. (1998) (30)
Potentially inappropriate medication use in older patients with breast and colorectal cancer (2018) (30)
Elimination of clonogenic breast cancer cells from human bone marrow. A comparison of immunotoxin treatment with chemoimmunoseparation using 4‐hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres (1991) (30)
DIRAS3 (ARHI) Blocks RAS/MAPK Signaling by Binding Directly to RAS and Disrupting RAS Clusters. (2019) (30)
CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer. (1990) (30)
Differential signaling by an anti-p185(HER2) antibody and heregulin. (2000) (30)
Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cells (1989) (30)
Radioiodinated antibody targeting of the HER-2/neu oncoprotein. (1997) (29)
The role of tumor markers in gynecologic oncology. (1990) (29)
Clinical application of oxaliplatin in epithelial ovarian cancer. (2006) (29)
Perspectives on the future of cancer markers. (1993) (29)
Dissecting "PI3Kness": the complexity of personalized therapy for ovarian cancer. (2012) (29)
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference (2019) (29)
A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow. (1996) (29)
Ploidy analysis of epithelial ovarian cancers using image cytometry. (1992) (29)
Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c‐erbB‐2 (HER‐2/neu) gene product p185 (1999) (28)
ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteins. (2009) (28)
Eradication of microscopic lymph nodes metastases after injection of living BCG adjacent to the primary tumor. (1975) (27)
CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis (2015) (27)
In Vitro Assay of Endotoxin by the Inhibition of Macrophage Migration (1967) (27)
A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA). (2010) (27)
Antitumor activity of bacterial infection. I. Effect of Listeria monocytogenes on growth of a murine fibrosarcoma. (1975) (27)
Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability (2018) (27)
Oncogenes in ovarian cancer. (1992) (26)
Comparison of a rabbit heteroantiserum and a murine monoclonal antibody raised against a human epithelial ovarian carcinoma cell line. (1983) (26)
Coordinate elevation of serum markers in ovarian cancer but not in benign disease. (1991) (25)
Homologous and heterologous desensitization of proto‐oncogene cfos expression in murine peritoneal macrophages (1987) (25)
Phase II study of vinorelbine administered by 96‐hour infusion in patients with advanced breast carcinoma (1999) (25)
The early competence genes JE and KC are differentially regulated in murine peritoneal macrophages in response to lipopolysaccharide. (1987) (25)
Expression of alpha 6 and beta 4 integrins in serous ovarian carcinoma correlates with expression of the basement membrane protein laminin. (1996) (25)
HETEROGENEITY OF THE CELLULAR IMMUNE RESPONSE (1971) (25)
Recombinant leukocyte alpha interferon in advanced ovarian carcinoma. (1985) (24)
Enhanced arachidonic acid lipoxygenation by K562 cells stimulated with 12-O-tetradecanoylphorbol-13-acetate. (1983) (24)
Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells (2013) (24)
The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3‐induced dormant ovarian cancer xenografts (2019) (24)
SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters (2020) (24)
Targeting progesterone signaling prevents metastatic ovarian cancer (2020) (24)
The biology of ovarian cancer (1993) (24)
Immunologic approaches to the management of ovarian carcinoma. (1984) (24)
In vivo modeling of metastatic human high-grade serous ovarian cancer in mice (2020) (23)
Conquering cancer in our lifetime: new diagnostic and therapeutic trends. (2013) (23)
Molecular approaches to prevention and detection of epithelial ovarian cancer (1995) (23)
Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models (2016) (22)
Epac1 knockdown inhibits the proliferation of ovarian cancer cells by inactivating AKT/Cyclin D1/CDK4 pathway in vitro and in vivo (2016) (22)
Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cells (2017) (22)
Determination of proliferation index in advanced ovarian cancer using quantitative image analysis. (1993) (22)
Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer (2010) (22)
Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass (2000) (22)
Targeting Aurora kinases in ovarian cancer (2006) (22)
The tyrosine kinase activity of the C‐erbB‐2 gene product (p185) is required for growth inhibition by anti‐p185 antibodies but not for the cytotoxicity of an anti‐p185‐ricin‐a chain immunotoxin (1994) (21)
Project Zero Delay: a process for accelerating the activation of cancer clinical trials. (2009) (21)
Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action. (1993) (20)
Benzo[a]pyrene Metabolism: Enzymatic and Liquid Chromatographic Analysis and Application to Human Liver, Lymphocytes, and Monocytes (1977) (20)
In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer. (2005) (20)
CA 125 levels in menopausal women (1990) (20)
Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment (2010) (20)
Specific keynote: molecular therapeutics in ovarian cancer. (2003) (20)
Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. (2008) (20)
Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support (1996) (20)
Is OVX1 a suitable marker for endometrial cancer? (1997) (20)
Gynecologic tumor markers. (1990) (19)
Antitumor activity of bacterial infection. II. effect of Listeria monocytogenes on growth of a guinea pig hepatoma. (1975) (19)
The immunobiology and immunotherapy of ovarian cancer. (1991) (19)
6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers (2019) (19)
Soluble interleukin‐2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer (1995) (19)
Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, PTP-alpha expression. (1996) (19)
Heregulin-induced apoptosis (2002) (18)
Morphologic changes in draining lymph nodes and in lymphocyte cultures after sensitization with complete or incomplete Freund's adjuvant. Correlation with immunologic events in vivo and in culture. (1971) (18)
A study of the NB/70K and CA 125 monoclonal antibody radioimmunoassays for measuring serum antigen levels in ovarian cancer patients (1985) (18)
Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer (2019) (18)
The Emerging Role of HE4 in the Evaluation of Advanced Epithelial Ovarian and Endometrial Carcinomas (2014) (17)
Biomarker modulation in a nonhuman rhesus primate model for ovarian cancer chemoprevention. (2001) (17)
Human epididymis protein 4 antigen‐autoantibody complexes complement cancer antigen 125 for detecting early‐stage ovarian cancer (2019) (17)
Detection of tumor cells in the bone marrow of stage IV breast cancer patients receiving high-dose chemotherapy: the role of induction chemotherapy. (1995) (17)
The Immunobiology of Ovarian Carcinoma (1983) (16)
Coexpression of different antigenic markers on moieties that bear CA 125 determinants. (1991) (16)
A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast‐cancer cell lines (1992) (16)
Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. (2000) (16)
Amino Acid Deprivation-Induced Autophagy Requires Upregulation of DIRAS3 through Reduction of E2F1 and E2F4 Transcriptional Repression (2019) (16)
In Vivo Optical Detection and Spectral Triangulation of Carbon Nanotubes. (2017) (16)
Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer (2019) (16)
Effects of monoclonal antibody and complement treatment of human marrow on hematopoiesis in continuous bone marrow culture. (1985) (16)
A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer (2011) (16)
Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer. (2006) (16)
Reproducibility of SELDI Spectra Across Time and Laboratories (2011) (16)
Caspase-3 Substrates for Noninvasive Pharmacodynamic Imaging of Apoptosis by PET/CT. (2018) (15)
Conseusus statements on prognostic factors in epithelial ovarian carcinoma. Report of the Consensus Meeting organized by the European Society of Gynaecological Oncology, ESGO. (2000) (15)
Potentially inappropriate medications defined by STOPP criteria in older patients with breast and colorectal cancer. (2019) (15)
Monocyte chemotaxis mediated by formyl-methionyl-leucyl-phenylalanine conjugated with monoclonal antibodies against human ovarian carcinoma. (1983) (15)
Prevention of ovarian cancer. (1999) (15)
Ovarian cancer identified through screening with serum markers but not by pelvic imaging. (1999) (15)
Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. (2000) (14)
NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms (2015) (14)
Reactivity of epidermal growth factor receptor monoclonal antibodies with human uterine tissues. (1989) (14)
Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust. (2003) (14)
Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen. (1992) (14)
Subcellular Localization of p 27 kip 1 Expression Predicts Poor Prognosis in Human Ovarian Cancer (2005) (14)
High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support (1989) (14)
Imprinted tumor suppressor gene ARHI induces apoptosis correlated with changes in DNA methylation in pancreatic cancer cells. (2010) (14)
How will we recruit, train, and retain physicians and scientists to conduct translational cancer research? (2015) (14)
Translational research--traffic on the bridge. (2001) (14)
Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women (2020) (13)
OVX1 radioimmunoassay results are dependent on the method of sample collection and storage. (1999) (13)
Application of Monoclonal Antibodies to Autologous Bone Marrow Transplantation (1984) (13)
Directed evolution of cyclic peptides for inhibition of autophagy† (2021) (13)
IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming (2021) (13)
Oncology Nurse (2003) (13)
Detection of minimal residual breast cancer in bone marrow. (1992) (12)
DIRAS3-Derived Peptide Inhibits Autophagy in Ovarian Cancer Cells by Binding to Beclin1 (2019) (12)
Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. (2016) (12)
Specific keynote: chemoprevention of ovarian cancer: the journey begins. (2003) (12)
Transfection of Ovarian Cancer Cells with Tumor Necrosis Factor-α (TNF-α) Antisense mRNA Abolishes the Proliferative Response to Interleukin-1 (IL-1) but Not TNF-α (1994) (12)
Antigenic heterogeneity in human ovarian cancer. (1986) (12)
Nature of the immunogen in crystalline serum albumins. (1970) (12)
Correction to Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2 [Molecular Cell 61, 520-534, (2016)] (2016) (12)
Summary of symposium: Biology and therapy of ovarian cancer. (1991) (12)
Weekly high-dose paclitaxel(HD-P) has significant antitumor activity in inflammatory breast cancer (IBC) (2001) (12)
Chemotherapy: A new standard combination for recurrent ovarian cancer? (2010) (12)
Tissue distribution and characteristics of the CA 125 antigen (1988) (12)
A phase IIa study of a sequential regimen using azacitidine to reverse platinum resistance to carboplatin in patients with platinum resistant or refractory epithelial ovarian cancer (2008) (12)
Immunologic unresponsiveness in the adult guinea pig. IV. Induction of unresponsiveness with aggregated serum proteins. (1969) (12)
Radioimmunotherapy of Cancer (2003) (11)
Breast cancer cells are effectively purged from peripheral blood progenitor cells with an immunomagnetic technique. (1996) (11)
Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody. (1988) (11)
Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3 (2012) (11)
Immunohistochemical expression of TAG-72 in normal and malignant endometrium: correlation of antigen expression with estrogen receptor and progesterone receptor levels. (1989) (11)
Cancer medicine e.5 (2000) (11)
Local antitumor activity of a primary and an anamnestic response to a syngeneic guinea pig hepatoma. (1975) (11)
Analysis of RAS protein interactions in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders (2020) (11)
Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum. (1984) (11)
Combined chemoseparation and immunoseparation of clonogenic T lymphoma cells from human bone marrow using 2'-deoxycoformycin, deoxyadenosine, 3A1 monoclonal antibody, and complement. (1987) (10)
Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multiprotein Classifier for Ovarian Cancer Detection (2019) (10)
92225921 Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer (1993) (10)
Naturally soluble tumor antigens from guinea pig hepatomas: isolation and partial characterization. (1976) (10)
Carcinoma of the Pancreas (1985) (10)
Molecular approaches to management of epithelial ovarian cancer. (2000) (10)
The emerging role of monoclonal antibodies in the clinical management of epithelial ovarian carcinoma. (1987) (10)
Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis (2020) (10)
Aryl hydrocarbon (benzo(alpha)pyrene) hydroxylase in guinea pig peritoneal macrophages: benz(alpha)anthracene-induced increase of enzyme activity in vivo and in cell culture. (1973) (10)
Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer. (1996) (10)
An application of artificial neural networks in ovarian cancer early detection (2000) (10)
Monoclonal antibody purged autologous bone marrow transplantation for relapsed non i acute lymphoblastic leukemia (1985) (10)
Principles of Oncology Nursing (2000) (9)
National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Ovarian Cancer (2006) (9)
p53-based gene therapy of ovarian cancer: magic bullet? (1995) (9)
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β (2018) (9)
Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition (2020) (9)
A Review of Intraperitoneal Therapy of Human Ovarian Carcinoma (1983) (9)
Validation of Biomarker Panels for Ovarian Cancer A Framework for Evaluating Biomarkers for Early Detection : Updated (2011) (9)
Combination of 4-HPR and oral contraceptive in monkey model of chemoprevention of ovarian cancer. (2007) (9)
Destruction of syngeneic tumors by tuberculin-stimulated peritoneal exudate cells from guinea pigs immunized to Mycobacterium bovis (strain BCG). (1974) (9)
Presence of A-type and absence of C-type virus particles in a chemically induced guinea pig hepatoma. (1974) (9)
Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas. (2021) (8)
Prediction of the optimal timing of bone marrow reinfusion after high dose chemotherapy. (1986) (8)
The half-life of aryl hydrocarbon (benzo(a)pyrene) hydroxylase in human blood monocytes. (1976) (8)
A 2-stage ovarian cancer screening strategy using the risk of ovarian cancer algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value (2014) (8)
HL-A antigen frequency distribution in patients with gestational choriocarcinoma and their husbands. (1981) (8)
The Use of Tumor Markers in the Management of Patients with Gynecologic Carcinomas (1992) (8)
Biomarkers for ovarian cancer: new technologies and targets to address persistently unmet needs. (2010) (8)
Specificity of heteroantisera developed against purified populations of intact murine ovarian carcinoma cells. (1980) (8)
Principles of Cancer Rehabilitation Medicine (2000) (8)
Toward a chronotherapy of ovarian cancer. Part III: Salivary CA125 for chronochemotherapy by efficacy. (1992) (8)
Colorectal , and Ovarian Cancer Screening Trial Specimens Ovarian Cancer Biomarker Performance in Prostate , Lung , Updated (2011) (8)
National Cancer Institute Conference on Investigational Strategies for Detection and Intervention in Early Ovarian Cancer. (1993) (7)
Immunodiagnosis of ovarian tumors. (1990) (7)
A MYC-Driven Plasma Polyamine Signature for Early Detection of Ovarian Cancer (2021) (7)
Immunopharmacologic purging of breast cancer from bone marrow for autologous bone marrow transplantation. (1990) (7)
Circulating Cancer Biomarkers (2021) (7)
Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. (2014) (7)
OVX1 as a marker for early stage endometrial carcinoma (1994) (7)
Growth arrest induced by anti-HER2 antibody blocks breast cancer cells in the late G1 phase of the cell cycle (2005) (7)
Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer (2000) (7)
Development of a new sensitive immunoradiometric assay for CA125: Mixed use of two monoclonal antibodies reactive with separate epitopes (1988) (7)
Differential expression of CA125 and a novel serum tumor marker HE4 in epithelial ovarian cancer (2008) (7)
4‐HPR modulates gene expression in ovarian cells (2006) (7)
CA 125 serum levels correlate with second-look operations among ovarian cancer patients: A prospective multi-institutional study (1986) (7)
Progress in radioimmunotherapy. (1993) (7)
Complementary and coordinate markers for detection of epithelial ovarian cancers (1995) (7)
Phase I–II Vinorelbine (Navelbine®) by Continuous Infusion in Patients with Metastatic Breast Cancer: Cumulative Toxicities Limit Dose Escalation (2001) (7)
Detection of a novel marker in the bronchial secretions of patients with non‐small cell lung cancer using the 4B5 monoclonal antibody (1992) (6)
Immunoprophylaxis of Syngeneic Methylcholanthrene-induced Murine Sarcomas with Bacillus Calmette-Guérin and Tumor Cells (1980) (6)
Next steps in the early detection of ovarian cancer (2021) (6)
Antigenic heterogeneity among Burkitt's lymphoma cells surviving treatment with monoclonal antibody and complement. (1986) (6)
Tumor suppressor genes. (2009) (6)
OVX1 and CEA in Patients with Colon Carcinoma, Colon Polyps and Benign Colon Disorders (1998) (6)
Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody (1985) (6)
DIRAS3: An Imprinted Tumor Suppressor Gene that Regulates RAS and PI3K-driven Cancer Growth, Motility, Autophagy, and Tumor Dormancy (2021) (6)
A novel multiple biomarker assay for the detection of ovarian carcinoma. (2006) (6)
Recent advances in the immunodiagnosis of epithelial ovarian carcinoma (1985) (6)
In vitro treatment with monoclonal antibody prior to autologous bone marrow transplantation in acute lymphoblastic leukemia. (1983) (6)
Variant prostate carcinoma and elevated serum CA-125. (2014) (6)
Molecular genetic features of ovarian cancer. (1996) (6)
Autologous Bone Marrow Transplantation in Calla Positive Acute Lymphoblastic Leukemia (1984) (6)
The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells. (1992) (5)
Nonepithelial Ovarian Cancer (2003) (5)
Use of a panel of proteomic markers to improve the sensitivity of CA125 for detecting stage I epithelial ovarian cancer (2008) (5)
Abstract 1864: Feasibility of magnetic relaxometry for early ovarian cancer detection: preliminary evaluation of sensitivity and specificity in cell culture and in mice (2017) (5)
Immunotherapy of experimental cancer with BCG and surgery (1975) (5)
Immunobiology of Human Breast Cancer (1987) (5)
Subcellular Localization of p27 Expression Predicts Poor Prognosis in Human Ovarian Cancer (2005) (5)
Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines. (1998) (5)
Clinical Applications of Monoclonal Antibodies in Acute Leukemia a (1984) (5)
A large-scale multi-center independent validation study of a panel of seven biomarkers for the detection of ovarian cancer. (2006) (5)
Elevated serum levels of macrophage colony-stimulating factor and OVX1, 11 months prior to the diagnosis of stage IC ovarian cancer (1996) (4)
Validation of a multi-marker panel for early detection of ovarian cancer. (2016) (4)
Aryl hydrocarbon (benzo[a]pyrene) hydroxylase in guinea pig lymphoid tissue. (1981) (4)
Transfection of ovarian cancer cells with tumor necrosis factor-alpha (TNF-alpha) antisense mRNA abolishes the proliferative response to interleukin-1 (IL-1) but not TNF-alpha. (1994) (4)
Pharmacokinetics of a radioiodinated monoclonal antibody F(ab')2 fragment in a xenograft model with circulating antigen. (1989) (4)
Current challenges and future directions in the management of ovarian cancer: Proceedings of the first global workshop on ovarian cancer (2010) (4)
Structure-Based Design of Stapled Peptides That Bind GABARAP and Inhibit Autophagy. (2022) (4)
Spectral differences between epitopes in the cronomes of salivary CA130 and CA125. (1995) (4)
Biology and therapy with biologic agents in gynecologic cancer. (1992) (4)
Chemoprevention of ovarian cancer: The journey begins (2003) (4)
Monitoring epithelial ovarian cancer (1985) (4)
Intracolonic injection of BCG in the rhesus monkey. (1974) (4)
Brief Communication: Intracolonlc Injection of BeG in the Rhesus Monkey (1974) (4)
SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers (2022) (4)
Nuclear HKII-P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian Cancer (2021) (3)
Additive and synergistic interactions of monoclonal antibodies and immunotoxins reactive with breast and ovarian cancer. (1994) (3)
Long-term culture of human granulocytes and granulocyte progenitor cells. (1986) (3)
Principles of Bone Marrow Transplantation (2000) (3)
CA 125 levels in patients with ovarian carcinoma undergoing autologous bone marrow transplantation. (1989) (3)
Sensitive and specific detection of the 4B5 antigen in bronchial lavage specimens from patients with primary bronchogenic carcinoma (1992) (3)
Anti-HER 2 Antibody and Heregulin Suppress Growth of HER 2-Overexpressing Human Breast Cancer Cells through Different Mechanisms 1 (2000) (3)
Conclusions and recommendations from the Helene Harris Memorial Trust SixthBiennial International Forum on Ovarian Cancer, May 10–14, 1997, LosAngeles, California, USA (1997) (3)
High sensitivity and specificity of screening for ovarian cancer with the risk of ovarian cancer (ROC) algorithm based on rising CA125 levels. (1996) (3)
Abstract 2838: TP53 autoantibody can detect CA125 screen negative ovarian cancer cases and can be elevated prior to CA125 in preclinical ovarian cancer (2015) (3)
for the Detection of Early Stage Ovarian Cancer Three Biomarkers Identified from Serum Proteomic Analysis (2004) (3)
Utility of a novel serum tumor biomarker HE4 in patients with uterine cancer. (2006) (3)
Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors (2021) (3)
Screening for ovarian cancer. Multiple markers may outperform CA 125 alone. (1993) (3)
Toward salivary-urinary chronosensitivity testing: chronomes of OVX1, M-CSF and CA130. (1995) (3)
Biomarkers and clinical trial design. (2006) (3)
Adjuvant and Neoadjuvant Chemotherapy (2003) (2)
Expression of the tumor suppressor gene ARHI induces autophagic cell death in ovarian cancer cells (2005) (2)
Antigens associated with epithelial ovarian carcinomas. (1989) (2)
Principles of Cancer Pathology (2000) (2)
Abstract A43: DIRAS1 and DIRAS2 are tumor suppressor candidates that inhibit cell growth, motility, and proliferation while regulating autophagy in ovarian cancer. (2016) (2)
Reactivity of Polyclonal and Two Monoclonal Antibodies with Cell Subsets Isolated from Cystic Fluids of Ovarian Serous Neoplasms (1990) (2)
Advances in the detection of marrow micrometastases in breast cancer (1994) (2)
Recurrent Ovarian Cancer: When to Treat and How to Assess (2014) (2)
General keynote: molecular therapeutics and pharmocogenomics. (2003) (2)
Tumor necrosis factor-α and interferon-γ stimulate MUC 16 ( CA 125 ) expression in breast , endometrial and ovarian cancers through NF κ (2016) (2)
Cell growth regulation in ovarian cancer: tyrosine kinases, tyrosine phosphatases and tumour necrosis factor-α (1995) (2)
The Oncology Pharmacist (2003) (2)
The National Cancer Institute Early Detection Research Network: Two Decades of Progress (2020) (2)
Section 31: The Breast (2003) (2)
Molecular Pathogenesis of Ovarian Cancer (2014) (2)
Cellular expression of CA 125 and metastatic potential of endometrial adenocarcinoma (1989) (2)
Abstract 1585: Loss of CDK5 sensitizes ovarian cancer cells to paclitaxel by enhancing intracellular retention (2010) (2)
Molecular Pathogenesis of Epithelial Ovarian Cancer (2008) (2)
A Novel Salt Inducible Kinase 2 Inhibitor, ARN-3261, Sensitizes Ovarian Cancer Cell Lines and Xenografts to Carboplatin (2021) (2)
The Rehabilitation Specialist (2003) (2)
New approach to serotherapy of human ovarian carcinoma (1980) (2)
Serotherapy of ovarian cancer. (1988) (2)
Tumor Necrosis Factor a as an Autocrine and Paracrine Growth Factor for Ovarian Cancer : Monokine Induction of Tumor Cell Proliferation and Tumor Necrosis Factor a Expression 1 (2006) (2)
Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics (2022) (2)
Abstract 1151: IL-8, VEGF and IGF-1 play the important role in ARHI mediated-tumor dormancy in ovarian cancer (2016) (2)
p27Kip1 as a Biomarker and Target for Treatment of Cancer (2010) (1)
Molecular therapeutics in ovarian cancer (2003) (1)
Development of a Multiprotein Classifier for the Detection of Early Stage Ovarian Cancer (2022) (1)
Serotherapy and Bone Marrow Transplantation (1985) (1)
A blood-based metabolite panel for distinguishing ovarian cancer from benign pelvic masses. (2022) (1)
Directed Evolution of PD-L1-Targeted Affibodies by mRNA Display. (2022) (1)
Ovarian cancer prevention+early detection: Mission impossible? (2006) (1)
Medical Oncologist (2003) (1)
Prevention and early detection of ovarian cancer (2007) (1)
Detection and measurement of HER2+ breast cancer cells using tumor-targeted iron oxide nanoparticles and magnetic relaxometry. (2018) (1)
Abstract 1999: DIRAS3 induces autophagy and enhances sensitivity to anti-autophagic therapy in KRAS-driven pancreatic and ovarian carcinomas (2021) (1)
Abstract 4987: IL8, VEGF and IGF-1 rescue ovarian cancer cells undergoing ARHI-mediated- autophagic cell death (2015) (1)
Expression of p 53 in Cisplatin-resistant Ovarian Cancer Cell Lines : Modulation with the Novel Platinum Analogue ( 1 R , 2 R-Diaminocyclohexane ) ( trans-diacetato ) ( dichloro )-platinum ( IV ) 1 (1999) (1)
Correction: Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability (2020) (1)
Corrigendum: Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells (2018) (1)
Abstract 4540: Follicle-stimulating hormone (FSH) enhances the proliferation of epithelial ovarian cancer cells by activating transient receptor potential channel C3 (TRPC3) (2011) (1)
Abstract #5559: Unsaturated glycoside of genistein induces severe microtubule depolymerization and mitotic arrest in ovarian cancer cells (2009) (1)
Section 23: Central Nervous System (2003) (1)
Section 3: Cancer Etiology (2003) (1)
Abstract LB-176: HE4 antigen-autoantibody complexes complement CA125 for detecting early stage ovarian cancer and can be elevated with CA125 in preclinical ovarian cancer (2018) (1)
Section 1: Cancer Biology (2003) (1)
Abstract P6-01-05: Detection of HER2 positive tumor cells using functionalized iron oxide nanoparticles (2019) (1)
In reply [8] (2007) (1)
Facile real time detection of membrane colocalization of RAS superfamily GTPase proteins in living cells (2018) (1)
Comprar Holland-Frei Cancer Medicine 8th | Waun Ki Hong | 9781607950141 | Mcgraw-Hill Education (2010) (1)
Early detection of cancer. (2008) (1)
Abstract 2051: DNA (cytosine-5-)-methyltransferases 3A (DNMT3A) is a direct target of miR-194 in breast cancer (2010) (1)
Abstract 3032: A novel compound ARN-3236 inhibits SIK2 and sensitizes ovarian cancer to paclitaxel (2016) (1)
Systematic Review of Monitoring Criteria to Interpret CA125 Increments during First-Line Chemotherapy and the Subsequent Follow-Up Period among Patients with Advanced Epithelial Ovarian Cancer (2015) (1)
Molecular Diagnostics in Cancer (2017) (1)
Abstract 749: Highly potent and orally available SIK2 inhibitors block growth of human ovarian cancer cells in culture and xenografts (2014) (1)
Author Correction: Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation (2022) (1)
The Role of Angiogenesis, Growth Arrest and Autophagy in Human Ovarian Cancer Xenograft Models for Tumor Dormancy (2014) (1)
Abstract 3564: Silencing pfkfb2 enhances paclitaxel sensitivity by modulating metabolism of p53 wt ovarian and breast cancer cells and xenografts (2017) (1)
Aryl hydrocarbon hydroxylase in human monocytes (1976) (1)
Abstract 83: Structural and biochemical properties of DIRAS3 N-terminal extension that permit its function as a tumor suppressor of oncogenic K-RAS (2021) (1)
Abstract 4768: PARP inhibitor-induced autophagy provides an adaptive mechanism of drug resistance in preclinical models of ovarian cancer (2019) (1)
What is a surgical oncologist? (2006) (1)
Abstract 3055: miR-495 functions as a novel regulator of the estrogen and progesterone receptorsin human breast cancers. (2013) (1)
Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome (2012) (1)
SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK (2022) (1)
Elevation of CA-125 prior to recurrence of ovarian cancer (1985) (1)
Abstract 4288: Targeted therapy against aldehyde dehydrogenase in ovarian cancer (2010) (1)
Section 34: Hematopoietic System (2003) (1)
A study of the NB/7OK and CA 125 monoclonal antibody radioimmunoassays for measuring serum antigen levels in ovarian cancer patients. (1985) (1)
Using tumor markers in cancer screening and follow-up (1999) (1)
Abstract 324: SIK2 inhibitors regulate DNA repair pathway and sensitize ovarian cancer to PARP1 inhibitors (2018) (1)
Reply to Davies et al (1985) (1)
Abstract 3816: Corilagin could help to overcome PARP inhibitor resistance by inhibiting ERK signaling pathways (2019) (0)
Cancer Prevention Research: The Forefront of Prevention Science, January 2015 (2015) (0)
Section 24: The Eye (2003) (0)
Perception of risk, cancer worry, anxiety, and acceptability of screening among low-risk women undergoing ovarian cancer screening with the risk of ovarian cancer algorithm (2012) (0)
Characterization of the ARHI tumor-suppressor as a target for gene therapy in ovarian cancer (2002) (0)
801 ABSENCE OF COMMON ALL ANTIGEN ON NORMAL PLURIPOTENTIAL MYELOID, ERYTHROID AND GRANULOCYTE PROGENITORS (1981) (0)
Immunoprophylaxis of syngeneic methycholanthrene-induced murine sarcomas with Bacillus Calmette-Guérin and tumor cells. (1980) (0)
If looks could kill: morphologic subtypes of high-grade serous ovarian cancer (2021) (0)
Section 22: Societal Oncology (2003) (0)
Abstract B43: A serum protein biomarker signature for the detection of early stages of ovarian cancer (2020) (0)
PROCEEDINGS, XI INTERNATIONAL CANCER CONGRESS, FLORENCE 1974 (1975) (0)
Interindividualand IntraindividualVariationsin Aryl HydrocarbonHydroxylasein Monocytesfrom Monozygoticand DizygoticTwins (1977) (0)
Serum 125Ca levels correlated with survival in epithelial ovarian cancer (1987) (0)
Section 12: Chemotherapeutic Agents (2003) (0)
Section 36: Unknown Primary Site (2003) (0)
Section 4: Cancer Epidemiology, Prevention, and Screening (2003) (0)
Section 39: Infection in the Cancer Patient (2003) (0)
Abstract 2515: DIRAS3 suppresses ovarian cancer cell growth through the inhibition of fibronectin-mediated FAK/AKT signaling (2023) (0)
Surrogate End Points (2003) (0)
Abstract 4263: Autophagic ovarian cancer cells exhibit substantially enhanced sensitivity to ALK inhibition (2019) (0)
Abstract 3313: Autophagic ovarian cancer cells exhibit substantially enhanced sensitivity to Crizotinib (2017) (0)
Cytotoxic T-Lymphocytes Derived from Patients with Breast Adenocarcinoma Recognize an Epifope Present on the Protein Core of a Mucin Molecule Preferentially Expressed by Malignant Cells1 (2006) (0)
Part I Cardinal Manifestations (2003) (0)
Abstract 4670: Combinations of kinase siRNAs potentiates paclitaxel sensitivity in ovarian cancer (2016) (0)
Gynecologic Oncologist (2003) (0)
JAMA Peer Reviewers for 2003 (2017) (0)
Principles of Endocrine Therapy (2000) (0)
Abstract 888: Volumetric reconstruction of targeted nanoparticles for superparamagnetic relaxometry (2017) (0)
Immunoprophylaxis of SyngeneicMethyicholanthrene-induced Murine Sarcomaswith BacillusCalmette-GuÃ©rin andTumorCells (1980) (0)
Section 33: Bone And Soft Tissue (2003) (0)
The Radiation Oncologist (2003) (0)
Monocyte chemotaxis mediated by f-MET-LEU-PHE (fMLP) conjugated with monoclonal anti-bodies against human ovarian carcinoma (1982) (0)
Biomarkers of 4-hpr in response of ovarian carcinoma ov-ca 433 cells (2003) (0)
Overexpression and mutation of the p53 oncogene in endometrial adenocarcinoma (1992) (0)
Abstract IA15: Early detection of ovarian cancer: An update (2018) (0)
Author lndex Vol. 17, 1996 (1996) (0)
Abstract LB-119: Single-cell live imaging of paclitaxel-resistant cancer cell generation (2016) (0)
Inhibition of the phosphatidylinositol 3’-kinase (PI3K) signaling pathway selectively enhances paclitaxel-induced apoptosis by modulating AKT and BAD phosphorylation in ovarian cancer cells (2004) (0)
Section 27: The Thorax (2003) (0)
Nomenclature: Systeme Internationale (SI) Units (2003) (0)
Section 5: Clinical Trials and Outcomes Assessment (2003) (0)
Fundamental Science, Clinical Science, and Medical Art (2003) (0)
Ovarian Cancer α Growth-Regulated Oncogene Lysophosphatidic Acid Is a Major Regulator of Updated (2006) (0)
Abstract AP08: DEVELOPMENT OF A MULTI-PROTEIN CLASSIFIER FOR OVARIAN CANCER DETECTION BY SIMULTANEOUS MEASUREMENT OF 92 SERUM PROTEINS ON PROSEEK MULTIPLEX ONCOLOGY II PLATES (2019) (0)
Perspectives on the Futureof CancerMarkers (1993) (0)
Abstract 2182: Epigenetic regulation and growth suppression by NDN, an imprinted tumor suppressor gene whose expression is decreased in epithelial ovarian cancers (2012) (0)
Section 8: Surgical Oncology (2003) (0)
Abstract 2527: Potent, highly selective peptidomimetic prodrugs targeting the SH2 domain of Stat3 decrease vasculogenic mimicry, invasion, and anchorage independent growth of cancer cells (2010) (0)
Abstract 3827: Histone methytransferase SMYD3 promotes invasion in ovarian carcinoma spheroids (2015) (0)
Chemosensitization FOXO 3 a-Dependent Mechanism of E 1 A-Induced Updated (2011) (0)
(Invited) Developing Short-Wave Infrared Fluorescent Immunoprobes Based on Single-Walled Carbon Nanotubes (2015) (0)
Abstract 3573: Urine and serum biomarkers as early detection tools for ovarian cancer (2012) (0)
Section 16: Bone Marrow Transplantation (2003) (0)
Abstract 3779: ARHI-induced autophagy is mediated through activation of FoxO3a and induction of its target genes to promote the formation of autophagic complexes (2011) (0)
Part III Cancer Diagnosis (2003) (0)
10th Biennial Helene Harris Memorial Trust meeting. (2006) (0)
DIRAS3 (DIRAS family, GTP -binding RAS -like 3) (2011) (0)
Section 32: The Skin (2003) (0)
Abstract 1669: DIRAS family members inhibit cell growth and proliferation while inducing autophagy in human ovarian cancer cells. (2013) (0)
Therapy with Unmodified Monoclonal Antibodies (2003) (0)
Section 25: Endocrine Glands (2003) (0)
H. THE ROLE OF ADJUVANT. LYMPHOCYTE STIMULATION IN CUTANEOUS BASOPHIL HYPERSENSITIVITY* (2003) (0)
Abstract 3762: Downregulation of TRPC3 enhances sensitivity to cisplatin and inhibits motility in epithelial ovarian cancer (2014) (0)
Erratum to “Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust” [European Journal of Cancer, 39 (2003) 1818–1827] (2004) (0)
The Primary Physician (2003) (0)
Barriers to Successful Serotherapy (2003) (0)
Section 37: Pediatric Oncology (2003) (0)
Abstract 5433: Knockdown of the glycolytic enzyme PFKFB2 induces growth inhibition and enhances paclitaxel sensitivity in ovarian cancer cells. (2013) (0)
H. THE ROLE OF ADJUVANT. LYMPHOCYTE STIMULATION IN CUTANEOUS BASOPHIL HYPERSENSITIVITY* (2003) (0)
Tumor and Stem Cell Biology FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization (2011) (0)
Abstract 5105: The imprinted tumor suppressor gene NDN inhibits cell motility in ovarian cancer by reactivating FAK and RhoA (2015) (0)
Part V Multidisciplinary Management (2003) (0)
Nonsense mediated decay defines deleterious TP53 mutations and tumor aggressiveness in ovarian cancer (2011) (0)
Abstract 5210: Novel SIK2 inhibitors sensitize ovarian and breast cancer to PARP inhibitors (2020) (0)
Overexpression of HER-2/neu in endometrial carcinoma is associated with poor prognosis (1991) (0)
Abstract 3599: Helical stapled peptides derived from DIRAS3 block KRAS dimerization and downstream MEK/ERK signaling in pancreatic and ovarian carcinomas (2022) (0)
The Psycho-oncologist (2003) (0)
Section 10: Medical Oncology (2003) (0)
Section 13: Biotherapeutics (2003) (0)
MIB- 1 in Advance d Ovaria n Cance r Usin g Quantitativ e Imag e Analysi s (2016) (0)
Abstract B20: Simultaneous measurement of 92 serum protein biomarkers for the development of a multiprotein classifier for ovarian cancer detection (2018) (0)
Abstract 912: Macrophage inhibitory factor (MIF), osteopontin (OPN) and anti-interleukin-8 (IL-8) autoantibodies (AAb) complement CA125 for detection of early-stage ovarian cancer (2019) (0)
ARHI (DIRAS 3), an Imprinted Tumor Suppressor Gene, Binds to Importins, and Blocks Nuclear Translocation of Stat3 (2008) (0)
Cytotoxic T-Lymphocytes Derived from Patients with Breast Adenocarcinoma Recognize an Epifope Present on the Protein Core of a Mucin Molecule Preferentially Expressed by Malignant Cells 1 (2006) (0)
One-Pot, One-Step Synthesis of Drug-Loaded Magnetic Multimicelle Aggregates (2022) (0)
Combined Purging Approaches in Autologous Transplantation (2020) (0)
Distribution of murine MUC16, a homolog of human ovarian cancer marker CA125, in adult murine reproductive tissues (2006) (0)
(Invited) Noninvasive Detection and Spectral Triangulation of Single-Walled Carbon Nanotubes In Vivo (2017) (0)
Elimination of Malignant Cells from Bone Marrow Ex Vivo (2003) (0)
Immunoprophylaxisof SyngeneicMethyicholanthrene-inducedMurine Sarcomaswith BacillusCalmette-GuÃ©rin and Tumor Cells (2006) (0)
Section 17: Psycho-Oncology (2003) (0)
Molecular therapeutics and pharmocogenomics (2003) (0)
Genetic and epigenetic regulation of two imprinted tumor suppressor genes - ARHI and PEG3 - in ovarian cancer (2006) (0)
The ARHI tumor suppressor gene may prevent nuclear translocation of p-STAT3 by antagonizing the interaction of Ran with importin proteins (2007) (0)
Section 38: Complications of Cancer and its Treatment (2003) (0)
Clinical application of oxaliplatin in epithelial ovarian cancer (2006) (0)
A novel tumor suppressor gene ARHI (DIRAS3) enhances polymerization of microtubules and increases the anti-tumor activity of paclitaxel (2007) (0)
Increased arachidonic acid lipoxygenation by phorbol myristat acetate (PMA)-stimulated K562 cells (1982) (0)
Clinical and laboratory directions for ovarian cancer research. (1994) (0)
Abstract 4028: ARHI plays a critical role in ovarian cancer tumor dormancy by inhibition of angiogenesis switch (2015) (0)
Subject Index Vol. 17, 1996 (1996) (0)
HER2 signaling regulates different angiogenic factors through different pathways in breast cancer cells (2005) (0)
CA 125: History, Current Status, and Future Prospects (2020) (0)
Synergistic antitumor activity of manhu breast cancer immunotoxins (1990) (0)
Part IX Informatics (2003) (0)
Comprar Holland Frei Cancer Medicine Review | Emil Frei, III | 9781550093094 | BC Decker (2007) (0)
Abstract 4993: ARHI is required for induction of beclin-1/PI(3)K class III-mediated autophagy (2010) (0)
Section 14: Endocrine Therapy (2003) (0)
Autophagy and Cancer Chemotherapy: Inhibition or Enhancement? (2016) (0)
455 ARHI gene therapy and paclitaxel exert additive cytotoxicity for breast cancer cells through caspase-independent and caspase-dependent apoptotic mechanisms (2004) (0)
Update of Recommendat ions for the Use of Tumor Markers in Breast and Colorecta l Cancer : Cl in ica l Pract ice Guidel ines of the American Socie ty of Cl in ica l Oncology * (2001) (0)
Abstract 4766: Follicle stimulating hormone (FSH) inhibits apoptosis in ovarian cancer cell through regulating OCT4 stem cell signal pathway. (2013) (0)
Regulation of growth of normal ovarian epithelium and ovarian cancer cell lines by transforming growth factor-β (1991) (0)
Section 21: Pain and Palliation (2003) (0)
Section 35: Neoplasms in Aids (2003) (0)
Allele-Specific Reprogram ming of Cancer Metabolism by the Long Non-coding RNA CCAT 2 Graphical (2016) (0)
A radioimmunoassay for ovarian cancer. (1984) (0)
Abstract 4067: Integrated microfluidic bead-based immunosensor for multiplexed determinations of ovarian cancer biomarkers at the point-of-care (2012) (0)
Summary Remarks (1998) (0)
Laws of Therapeutics (2003) (0)
Abstract 3659: DIRAS1 and DIRAS2 are novel ovarian cancer tumor suppressors that regulate cell growth, motility and autophagy (2016) (0)
A multivariate longitudinal algorithm for early detection of ovarian cancer using multiple biomarkers. (2011) (0)
JAMA Peer Reviewers in 2004 (2016) (0)
Summary of the first Emil J Freireich symposium. (1997) (0)
Abstract 1325: DIRAS3 (ARHI) is required for amino acid-mediated autophagy and nutrient deprivation in dormant ovarian cancers (2018) (0)
Abstract 2311: NDN, an imprinted tumor suppressor gene inhibits ovarian cancer cell growth and motility and is downregulated by genetic and epigenetic mechanisms (2014) (0)
90270415 CA 125 levels in menopausal women (1991) (0)
Section 6: Cancer Pathology (2003) (0)
Section 2: Cancer Immunology (2003) (0)
Abstract 3473: Intra-person and inter-person biomarker variation for modeling longitudinal values of ovarian cancer early detection biomarkers. (2013) (0)
Medical Oncologist's Role (2003) (0)
Contents, Vol. 17, 1996 (1996) (0)
Current research and treatment for epithelial ovarian cancer. A position paper from the Helene Harris Memorial Trust (vol 39, pg 1818, 2003) (2004) (0)
Neoplasms of the Eye (2000) (0)
Abstract 3495: Multiplexed detection of early-stage ovarian cancer biomarkers using a microfluidic bead-based immunosensor. (2013) (0)
Section 15: Gene Therapy (2003) (0)
[Radiation treatment of malignant kidney tumors]. (1984) (0)
The Salmonella mutagenesis test (SMT) and CFU-GM assay as a guide for bone marrow re-infusion in the autologous transplantations setting (1985) (0)
Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models (2016) (0)
The relationship between tumor immunogenicity and the appearance of splenic immunosuppressor cells in tumor bearing mice. Abstr. (1977) (0)
Regulation of ovarian carcinoma-associaited proteinases: Cell surface-mediated proteolysis by plasma membrane localized matrix metalloproteinase-2 and urinary-type plasminogen activator (1994) (0)
Part VI Cancer Management (2003) (0)
Section 41: Oncology and Informatics (2003) (0)
Section 30: Female Reproductive Organs (2003) (0)
Abstract 3456: MUC16/CA125, TNFα and IFNγ are co-expressed in malignant gynecologic neoplasms (2015) (0)
Chemotactic anti-tumor antibodies: in vitro results with four different antibody preparations. (1985) (0)
Section 28: Gastrointestinal Tract (2003) (0)
Phase I S tudy o f S tealth L iposomal D oxorubicin i n Combination W ith G emcitabine i n t he T reatment o f Patients W ith M etastatic B reast C ancer (2001) (0)
Abstract 438: Development of an autoantibody panel that reflects disease pathogenesis in ovarian cancer (2016) (0)
Abstract 4083: Crizotinib improves the therapeutic efficacy of olaparib in ovarian cancer (2020) (0)
Abstract B22: Establishment of Patient-Derived Xenograft (PDX) Models of Ovarian Cancer (2016) (0)
Abstract 1247: ARHI downregulates PI3K and Ras-MAP signaling and induces autophagy by promoting integrin and EGFR membrane protein degradation (2012) (0)
Reply to Comment on “Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer” Cancers 2019, 11, 596: Markers for Early Detection of Ovarian Cancer (2019) (0)
Immunotoxins and Radionuclide Conjugates for Inhibiting Growth of Ovarian and Breast Cancer Cells That Overexpress HER-2 1 (2000) (0)
High‐dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer (1991) (0)
Section 18: Oncology Nursing (2003) (0)
Abstract 887: Magnetic relaxometry detection of stealth, antibody-targeted micellar iron oxide nanoparticles in-vivo (2017) (0)
Synergistic Interaction between Anti-p 185 HER-2 Ricin A Chain Immunotoxins and Radionuclide Conjugates for Inhibiting Growth of Ovarian and Breast Cancer Cells That Overexpress HER-21 (2000) (0)
Part VIII Complications (2003) (0)
Critical Questions in Ovarian Cancer Research and Treatment: Report of an AACR Special Conference (2019) (0)
Establishment and Characterization of Cancer Cell Cultures and Xenografts Derived from Primary or Metastatic Mullerian Cancers 1 (2003) (0)
Abstract 1680: ARHI-induced autophagy enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts. (2013) (0)
Clinical factors affecting HE4 and CA125 in women at high risk of developing ovarian cancer. (2013) (0)
Section 26: Head and Neck (2003) (0)
Abstract 4679: Integrin and FAK signaling regulate ARHI-induced autophagy (2010) (0)
Author index (2010) (0)
395 POSTER CpG island methylator phenotype (CIMP): a novel biomaker to predict new therapy for breast cancer (2006) (0)
Section 29: Genitourinary Tract (2003) (0)
Section 19: Cancer Rehabilitation Medicine (2003) (0)
Immunologic Unresponsiveness in the Adult Guinea Pig (1965) (0)
Changes in perceptions of screening over time among average-risk women undergoing ovarian cancer screening using the risk of ovarian cancer algorithm (2013) (0)
HER2 antibodies pertuzumab and trastuzumab differ in their effect on cell signaling and growth inhibition in breast cancer cells (2006) (0)
InVitro AssayofEndotoxin bytheInhibition of Macrophage Migration (1967) (0)
Abstract 4567: Urine biomarkers outperform serum biomarkers in the diagnosis of various human cancers (2010) (0)
A novel tumor suppressor gene ARHI induces autophagy in ovarian cancer (2006) (0)
1 Cardinal manifestations of cancer (2016) (0)
Author Correction: Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation (2018) (0)
Abstract 953: Knockdown of kinases that regulate microtubule stability and centrosome function enhance paclitaxel sensitivity in multiple ovarian cancer cell lines. (2013) (0)
Section 40: Oncologic Emergencies (2003) (0)
Transforming Growth Factor 131 Can Induce CIP1/WAF1 Expression Independent of the p53 Pathway (1994) (0)
Insurance coverage of screening mammography and Pap smears. The directors of North Carolina's University-based cancer centers speak out. (1991) (0)
Part IV Therapeutic Modalities (2003) (0)
Targeting therapies in cancer: Opportunities in ovarian cancer (2011) (0)
Abstract AS12: Integrating genomics, transcriptomics, and proteomics for the discovery of novel biomarkers to complement CA125 in ovarian cancer early detection (2015) (0)
Theory and Practice of Clinical Trials (2000) (0)
Breast Cancers Tumor Suppressor Gene in which the Function Is Lost in , an Imprinted ARHI Aberrant Methylation and Silencing of Updated (2003) (0)
Section 11: Chemotherapy (2003) (0)
Monitoring growth of human ovarian carcinoma with a radioimmunoassay for antigen(s) defined by a murine monoclonal antibody (0C125) (1983) (0)
Section 7: Imaging (2003) (0)
Serum Proteomics Yield New Biomarkers for Ovarian Cancer (2004) (0)
CEBP FOCUS Biomarkers and Strategies for Early Detection of Ovarian Cancer (2020) (0)
GRN300–001: Phase 1/1B evaluation of the safety, pharmacokinetics, and efficacy of GRN-300, a salt-inducible kinase inhibitor, alone and in combination with paclitaxel, in recurrent ovarian, primary peritoneal, and fallopian tube cancers. (2022) (0)
Principles of Multidisciplinary Management (2003) (0)
Therapy with Drug-Monoclonal Antibody Conjugates (2003) (0)
Invited Presentation: SWCNT-Based Fluorescent Immunoprobes for Short-Wave Infrared Cancer Detection (2014) (0)
Abstract 2097: ARHI (DiRAS3): A novel component in the formation of the autophagy initiation complex (2011) (0)
Abstract PR18: Survival of ARHI-induced dormant autophagic cell death in vivo requires permissive levels of VEGF, IL-8, and IGF-1 in the tumor microenvironment. (2016) (0)
Molecular targets for epithelial ovarian cancer (2015) (0)
Abstract 3317: Autophagy protects ovarian cancer cells from olaparib-induced toxicity (2017) (0)
SCC antigen. Summary remarks. (1998) (0)
Part II Scientific Foundation (2003) (0)
Clinical studies of an oncofetal antigen (DU-PAN-2) detected by a monoclonal antibody to pancreatic adenocarcinoma (1985) (0)
Section 20: Multidisciplinary Management (2003) (0)
Abstract LB-296: Discovery of ARN-3261 as a potent, selective, orally available SIK2 inhibitor for treating ovarian, endometrial, primary peritoneal, fallopian tube, and triple negative breast cancers (2017) (0)
The Pediatric Oncologist (2003) (0)
Abstract 4000: Trastuzumab targeting of HER2 upregulates miRNA-194 and downregulates profilin 2 and DNMT3A in HER2 positive breast cancer (2011) (0)
Section 9: Radiation Oncology (2003) (0)
Use of Immunotoxins in Combinationto Inhibit Clonogenic Growth of Human Breast Carcinoma Cells1 (2006) (0)
Molecular Mechanisms of Pathogenesis and Progression of Epithelial Ovarian Cancer (2003) (0)
Chapter 6 – Ovarian Cancer Screening (2010) (0)
Part VII Pediatric Oncology (2003) (0)

This paper list is powered by the following services:

Other Resources About Robert C. Bast Jr.

What Schools Are Affiliated With Robert C. Bast Jr.?

Robert C. Bast Jr. is affiliated with the following schools:

Robert C. Bast Jr.'s Academic­Influence.com Rankings